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    Chronic lung disease includes a wide 
variety of persistent conditions, such as: 
pulmonary tuberculosis, asthma, cystic 
fibrosis, chronic obstructive pulmonary 
disease, lung cancer, etc. Current 
pharmacotherapy, although effective, does 
not contribute to the complete restoration of 
lung function. An advanced strategy would 
be the use of nanoparticles in pulmonary 
administration. 
Lung diseases, treatment, nanoparticles. 
Study of the available literature to highlight 
the types of nanoparticles possible to be used 
in the treatment of lung diseases.  
Bibliographic study of listed journals from electronic bases (Pubmed and Hinari) 
in the field of development of drug products related to nanoparticles as 
anticancer agents, antivirals, antituberculosis agents, antibiotics, steroids and 
current efforts to achieve lung-oriented medicine.   
Magnetic nanoparticles and dendrimers are 
promising vehicles for specific lung treatment.  
     Traditional pharmacotherapy used in lung 
diseases often faces limitations, and inadequate 
pharmacokinetics and insufficient release of 
specific drugs often lead to a poor response to 
treatment. In addition, an efficient vector system 
is a necessary condition for successful gene 
therapy, because genetic molecules are not easily 
released into cells without carriers and often 
degraded into biological fluids.  
      To solve these problems, nanoparticles are 
highly promising as drug carriers such as 
liposomes, micelles, polymeric nanoparticles, 
magnetic nanoparticles (fig.1), dendrimers (fig.2), 
and others. The main determinant for the in vivo 
distribution of inhaled nanoparticles is the 
aerodynamic diameter of the nanoparticles (20- 
100 nm). PEGylation of nanoparticles reduces 
their opsonization by immune cells and makes 
them able to enter the respiratory mucus.  
Fig. 1 Magnetic nanoparicles 
https://www.researchgate.net/figure/M
agnetic-nanoparticles_fig2_216213322 
Fig. 2. Dendrimers 
https://www.researchgate.net/figure/Structure-
of-dendrimers_fig3_327645542 
